Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000520767 | SCV000620224 | uncertain significance | not provided | 2017-08-28 | criteria provided, single submitter | clinical testing | The W87X variant in the YARS gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The W87X is observed in 3/66,740 alleles (0.0045%) from individuals of non-Finnish European background in the ExAC dataset, with no homozygous control individuals reported (Lek et al., 2016). We interpret W87X as a variant of uncertain significance. |
Invitae | RCV001242803 | SCV001415915 | uncertain significance | Charcot-Marie-Tooth disease, dominant intermediate C | 2019-10-31 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp87*) in the YARS gene. It is expected to result in an absent or disrupted protein product. This variant is present in population databases (rs776952611, ExAC 0.004%). This variant has not been reported in the literature in individuals with YARS-related conditions. ClinVar contains an entry for this variant (Variation ID: 451509). The current clinical and genetic evidence is not sufficient to establish whether loss-of-function variants in YARS cause disease. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |